Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Ipilimumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Ipilimumab as a study intervention. Browse Ipilimumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
640
Shown on this page
12
Current sort
Recently updated
Therapy scope
Ipilimumab
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Ipilimumab. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 469–480 of 640 matching trials for Ipilimumab.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 3 Interventional Results available

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

NCT02714218
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab 3 mg/kg IV, Ipilimumab 1 mg/kg IV, Nivolumab 1 mg/kg IV, Ipilimumab 3 mg/kg IV, Nivolumab 6 mg/kg IV
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
11
States / cities
Aurora, Colorado • Tampa, Florida • Fridley, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2022 · Synced Oct 30, 2026, 7:27 PM EDT
Completed Phase 2 Interventional

A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma

NCT04090775
View directory record Official record
Conditions
Metastatic Prostatic Adenocarcinoma
Interventions
Opdivo Injectable Product, Yervoy Injectable Product, Cytoxan, Cryosurgical freezing (cryosurgery)
Drug · Procedure
Lead sponsor
Rampart Health, L.L.C.
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Lancaster, California • Rochester, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 30, 2026, 7:27 PM EDT
Terminated Phase 2 Interventional Results available

Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis

NCT03903640
View directory record Official record
Conditions
Melanoma With Brain Metastasis
Interventions
Optune, Nivolumab, Ipilimumab
Device · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 30, 2026, 7:27 PM EDT
Terminated Phase 1 Interventional

An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

NCT03444753
View directory record Official record
Conditions
Advanced Cancer
Interventions
BMS-986299, Nivolumab, Ipilimumab
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
9
States / cities
La Jolla, California • Orange, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Oct 30, 2026, 7:27 PM EDT
Completed No phase listed Observational

Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study

NCT02780089
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
66
States / cities
Muscle Shoals, Alabama • Hot Springs, Arkansas • Long Beach, California + 59 more
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Oct 30, 2026, 7:27 PM EDT
Completed Phase 1 Interventional

ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors

NCT03525795
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
CPI-1205, ipilimumab
Drug
Lead sponsor
Constellation Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 30, 2026, 7:27 PM EDT
Completed Phase 2 Interventional Results available

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

NCT00084656
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
ipilimumab, Tyrosinase/gp100/MART-1 Peptides
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 120 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 30, 2026, 7:27 PM EDT
Not listed No phase listed Observational

GI Complications in Cancer Immunotherapy Patients

NCT02784366
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 30, 2026, 7:27 PM EDT
Withdrawn No phase listed Observational

Yervoy Pregnancy Surveillance Study

NCT02854488
View directory record Official record
Conditions
Melanoma
Interventions
Yervoy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 30, 2026, 7:27 PM EDT
Completed Phase 2 Interventional Results available

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma

NCT01927419
View directory record Official record
Conditions
Unresectable Melanoma, Metastatic Melanoma
Interventions
Nivolumab, Ipilimumab, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
19
States / cities
San Francisco, California • Orlando, Florida • Louisville, Kentucky + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 30, 2026, 7:27 PM EDT
Terminated Phase 1 Interventional

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

NCT01940809
View directory record Official record
Conditions
BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Dabrafenib, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Trametinib
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 30, 2026, 7:27 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

NCT03347123
View directory record Official record
Conditions
Solid Tumors
Interventions
Epacadostat, Nivolumab, Ipilimumab, Lirilumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Monica, California + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 30, 2026, 7:27 PM EDT

About this Ipilimumab clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Ipilimumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Ipilimumab.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Ipilimumab.